Nutex Health investors re-elect board, approve pay

Nutex Health Inc. held its annual stockholder meeting on April 23, 2026.

Rhea-AI Filing Summary

Nutex Health Inc. held its annual stockholder meeting on April 23, 2026. There were 5,628,591 common shares eligible to vote, and 3,900,175 shares were voted, representing about 69.29% of eligible shares.

All seven director nominees were elected to serve until the 2027 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the named executive officers. In addition, stockholders ratified Grant Thornton LLP as Nutex Health’s independent registered public accounting firm for the year ending December 31, 2026.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares eligible to vote: 5,628,591 shares Shares voted: 3,900,175 shares Voter participation: 69.29% +5 more

8 metrics

Shares eligible to vote 5,628,591 shares Eligible common shares at April 23, 2026 annual meeting

Shares voted 3,900,175 shares Voted at the annual meeting (~69.29% of eligible)

Voter participation 69.29% Percentage of eligible Nutex Health shares voted

Say-on-pay votes for 2,505,375 votes Advisory approval of named executive officer compensation

Say-on-pay votes against 126,612 votes Advisory compensation proposal opposition

Auditor ratification votes for 3,841,817 votes Ratification of Grant Thornton LLP for 2026 audit

Auditor ratification votes against 25,441 votes Opposition to Grant Thornton LLP ratification

Broker non-votes on Proposal 2 1,256,968 votes Broker non-votes on executive compensation advisory vote

Key Terms

broker non-votes, named executive officers, independent registered public accounting firm, emerging growth company, +1 more

5 terms

broker non-votes financial

"the number of abstentions and broker non-votes, each rounded to the nearest whole share"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

named executive officers financial

"The compensation of our named executive officers was approved, on an advisory basis"

Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.

independent registered public accounting firm financial

"Grant Thornton LLP was ratified as our independent registered public accounting firm for the year ending December 31, 2026"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

annual meeting of stockholders financial

"At the annual meeting of stockholders of Nutex Health Inc."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nutex Health (NUTX) stockholders vote on at the 2026 annual meeting?

Stockholders voted on electing seven directors, approving executive compensation on an advisory basis, and ratifying Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2026. All three proposals received sufficient support to pass.

How many Nutex Health (NUTX) shares were eligible and actually voted?

There were 5,628,591 Nutex Health common shares eligible to vote, and 3,900,175 shares were voted. This represents approximately 69.29% of the shares eligible to vote at the April 23, 2026 annual stockholder meeting.

Were all Nutex Health (NUTX) director nominees elected at the 2026 meeting?

Yes, all seven Nutex Health director nominees were elected for an approximate one-year term, expiring at the 2027 annual meeting. Each nominee, including Thomas T. Vo and Frank E. Jaumot, received more votes “for” than “withheld,” plus broker non-votes.

How did Nutex Health (NUTX) stockholders vote on executive compensation?

Stockholders approved Nutex Health’s named executive officer compensation on an advisory basis, with 2,505,375 votes for, 126,612 against, and 11,220 abstentions. There were also 1,256,968 broker non-votes recorded on this non-binding say-on-pay proposal.

Was Grant Thornton LLP ratified as Nutex Health (NUTX) auditor for 2026?

Yes. Stockholders ratified Grant Thornton LLP as Nutex Health’s independent registered public accounting firm for the year ending December 31, 2026, with 3,841,817 votes for, 25,441 against, and 32,917 abstentions and no broker non-votes.

What was the quorum level at Nutex Health’s (NUTX) 2026 annual meeting?

Quorum was achieved with 3,900,175 shares voted out of 5,628,591 eligible shares, representing roughly 69.29% participation. This level of turnout allowed the company to conduct official business and approve the proposals on directors, pay, and auditor ratification.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 04:05 PM EDT Learn about SEC filing dates

0001479681FALSE00014796812026-04-232026-04-23

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): April 23, 2026 

NUTEX HEALTH INC.  

(Exact name of registrant as specified in its charter) 

Delaware			001-41346			11-3363609
(State or Other Jurisdiction  of Incorporation)			(Commission File Number)			(I.R.S. Employer  Identification No.)

  

1776 Yorktown Street, Suite 700, Houston, Texas 77056 

(Address of principal executive offices) (zip code) 

(713) 660-0557 

(Registrant’s telephone number, including area code) 

N/A 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders

At the annual meeting of stockholders of Nutex Health Inc. (the "Company”) held on April 23, 2026, there were 5,628,591 shares of the Company’s common stock, par value $0.001 per share, eligible to vote, of which 3,900,175 shares, or approximately 69.29% of the Company’s shares eligible to vote, were voted. The matters voted upon, the number of votes cast for or against, and the number of abstentions and broker non-votes, each rounded to the nearest whole share, were as stated below:

1.Each of our seven director nominees was elected for an approximate one-year term expiring at the 2027 annual meeting of stockholders.

Nominee						For						Withheld						Broker Non-Votes
Thomas T. Vo						2,554,009						89,198						1,256,968
Warren Hosseinion						2,512,649						130,558						1,256,968
Cheryl Grenas						2,555,905						87,302						1,256,968
Michael L. Reed						2,556,927						86,280						1,256,968
Scott J. Saunders						2,532,892						110,315						1,256,968
Kelvin Spears						2,525,003						118,204						1,256,968
Frank E. Jaumot						2,623,902						19,305						1,256,968

2. The compensation of our named executive officers was approved, on an advisory basis.

For						Against						Abstain						Broker Non-Votes
2,505,375						126,612						11,220						1,256,968

3. Grant Thornton LLP was ratified as our independent registered public accounting firm for the year ending December 31, 2026.

For						Against						Abstain						Broker Non-Votes
3,841,817						25,441						32,917						—

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: April 23, 2026			NUTEX HEALTH INC.
			By:			/s/ Jon C. Bates
						Jon C. Bates  Chief Financial Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 1.7 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT 22.0 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT 12.7 KB